HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy ; volume:9 ; number:1 ; day:10 ; month:12 ; year:2009 ; pages:1-12 ; date:12.2009
BMC cancer ; 9, Heft 1 (10.12.2009), 1-12, 12.2009
- Creator
- Contributor
-
Wiegand, Kimberly C.
Vang, Russell
Ronnett, Brigitte M.
Adamiak, Anna
Köbel, Martin
Kalloger, Steve E.
Swenerton, Kenneth D.
Huntsman, David G.
Gilks, C Blake
Miller, Dianne M.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-9-433
- URN
-
urn:nbn:de:1111-2016030350091
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- McAlpine, Jessica N.
- Wiegand, Kimberly C.
- Vang, Russell
- Ronnett, Brigitte M.
- Adamiak, Anna
- Köbel, Martin
- Kalloger, Steve E.
- Swenerton, Kenneth D.
- Huntsman, David G.
- Gilks, C Blake
- Miller, Dianne M.
- SpringerLink (Online service)
Other Objects (12)
A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary
Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie
A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary
Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie
A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary
Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2